- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02394600
The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant demonstrates understanding and has provided an appropriately signed and dated informed consent.
- Male or Female, 18 to 65 years of age, at time of the Screening visit.
- Participant has a history of at least moderate allergic rhinoconjunctivitis due to hypersensitivity to birch pollen for a minimum of 2 years.
- Participant responds to the birch pollen and timothy grass pollen through a standard skin prick test administered at the Screening visit. A positive test will be defined as a wheal diameter at least 5mm or larger than the negative control (normal saline) wheal. A historical skin-prick test performed within three-hundred sixty-five (365) days or one (1) year at the site will be accepted in lieu of performing a new skin prick test.
- Participant understands and is willing, able and likely to comply with study procedures and restrictions.
Participant, if female, has a negative urine pregnancy test at Visit 1 and is willing to use a medically acceptable form of birth control. Acceptable methods of birth control for this study include:
- oral, patch, or intra-vaginal hormonal contraceptives
- Norplant System®
- Depo-Provera®
- IUD
- double barrier method
- abstinence
- surgically sterile females (hysterectomy or tubal ligation)
- > 1 year post-menopausal females
- same sex partner
- partner vasectomy (> 3 months)
- Participant is healthy as determined by pre-study medical history, physical examination and vital signs.
- Participant is able to read, comprehend, and record all information in English.
- Participant has a serum specific IgE level to both birch and timothy grass of ≥0.7 ku/L.
Exclusion Criteria:
- Has significant current nasal or ocular symptoms that the study doctor associates with perennial allergic or non-allergic rhinitis.
- Female participant who is pregnant or lactating.
- Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. This includes a clinically relevant medical or surgical history or presence of other respiratory disease (exceptions made for asthma and allergic rhinitis as defined in further exclusion criteria), or gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, immunological, dermatological, connective tissue diseases or disorders, or a history of malignancy within the past 5 years, with the exception of non-melanoma skin cancer.
- Has any significant abnormalities found during physical exam as determined by the investigator.
- Has a current medical history of significant pulmonary disease and/or active asthma requiring daily drug therapy. Mild, intermittent asthma is permitted (managed with short acting beta-agonist less than 3 times per week). Isolated exercise-induced bronchospasm is also permitted.
- Has received an investigational drug within the last thirty (30) days.
- Has had use of immunotherapy containing grass or birch within the last 3 years.
- Has significant nasal polyps, nasal septal perforation, or nasal tract malformations as noted on physical exam.
- Administration of adrenaline (epinephrine) is contraindicated (e.g. participants with acute or chronic symptomatic coronary heart disease or concomitant beta-blocker therapy).
- Is unlikely to cooperate with the requirements of the study including having the ability to communicate with the investigator appropriately.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Grastek®
48 participants will receive Grastek® once per day for 120 days.
Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense).
This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
|
one tablet daily for four months
|
Placebo Comparator: Placebo
48 participants will receive placebo once per day for 120 days.
|
one tablet daily for four months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Total Nasal Symptom Score (TNSS) From Baseline to Post-treatment.
Time Frame: 4 months
|
To determine the effect of 4 months of treatment with Grastek® on the symptoms of birch pollen induced AR in participants with both timothy grass pollen-induced and birch pollen-induced allergen rhinitis (AR) TNSS is comprised of the sum of 4 symptoms: runny nose, itchy nose sneezing and nasal congestion. Each of these symptoms are evaluated based on a 4 point Likert scale from 0-3. 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. TNSS can therefore have a range from 0 to 12. |
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of Blood Samples for Potential Biomarkers by Comparing Baseline and Post-treatment Samples.
Time Frame: 4 months
|
To determine potential biomarkers predictive of clinical efficacy for birch pollen-induced AR following treatment with Grastek®
|
4 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne K Ellis, MD, Queen's University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EEU-MERCK 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinoconjunctivitis
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Immunomic Therapeutics, Inc.CompletedAllergic RhinoconjunctivitisUnited States
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
ALK-Abelló A/SCompleted
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
Clinical Trials on Grastek®
-
Virginia Commonwealth UniversityTerminatedImmunologic DesensitizationUnited States
-
AbbottCompletedSeasonal Allergic RhinitisRussian Federation
-
ALK-Abelló A/SCompleted
-
Clinique Spécialisée en Allergies de la CapitaleALK-Abelló A/SCompleted
-
Chong Kun Dang PharmaceuticalCompleted
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of